Sera Prognostics Inc
NASDAQ:SERA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sera Prognostics Inc
PP&E Net
Sera Prognostics Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sera Prognostics Inc
NASDAQ:SERA
|
PP&E Net
$3.6m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
PP&E Net
$5.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
PP&E Net
$5.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
PP&E Net
$7.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
PP&E Net
$3.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
19%
|
CAGR 10-Years
16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
PP&E Net
$5.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
Sera Prognostics Inc
Glance View
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 115 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The firm's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.
See Also
What is Sera Prognostics Inc's PP&E Net?
PP&E Net
3.6m
USD
Based on the financial report for Dec 31, 2025, Sera Prognostics Inc's PP&E Net amounts to 3.6m USD.
What is Sera Prognostics Inc's PP&E Net growth rate?
PP&E Net CAGR 3Y
-10%
Over the last year, the PP&E Net growth was 92%. The average annual PP&E Net growth rates for Sera Prognostics Inc have been -10% over the past three years .
